Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

The Lancet

Volumn 373, Issue 9660, 2009, Pages 309-317

  Collet, Jean Philippe ^a   Hulot, Jean Sébastien ^a   Pena, Anna ^a   Villard, Eric ^a   Esteve, Jean Baptiste ^a   Silvain, Johanne ^a   Payot, Laurent ^b   Brugier, Delphine ^a   Cayla, Guillaume ^a   Beygui, Farzin ^a   Bensimon, Gilbert ^a   Funck Brentano, Christian ^a   Montalescot, Gilles ^a  

^a INSERM   (France)

^b Montreuil Intercommunal Hospital Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; DEMOGRAPHY; DNA POLYMORPHISM; DRUG ELUTING STENT; DRUG WITHDRAWAL; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 58249135635     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61845-0     Document Type: Article

References (43)

1. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
2. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
3. Angiolillo D.A., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
4. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
5. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
6. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 48 (2006) 931-938
7. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
8. Lotrionte M., Biondi-Zoccai G.G., Agostoni P., et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 100 (2007) 1199-1206
9. Wiviott S.D., Braunwald E., Mccabe C.H., et al., for the Triton-Timi 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
10. Bonello L., Dignat-George F., Camoin-Jau L., Barragan P., Arques S., and Paganelli F. Adjusted clopidogrel loading dose to platelet reactivity measure decrease the rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multi centric randomized, prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
11. Hollopeter G., Jantzen H.M., Vincent D., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
12. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
13. Savi P., Labouret C., Delesque N., Guette F., Lupker J., and Herbert J.M. P2Y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283 (2001) 379-383
14. Brandt J.T., Close S., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
15. Kim K., Park P., Hong S., and Park J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84 (2008) 236-2342
16. Fayer Rehmel J.L., Eckstein J.A., Farid N.A., et al. Interaction of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34 (2006) 600-607
17. Fontana P., Hulot J.S., De Moerloose P., and Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5 (2007) 2153-2155
18. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
19. Frere C., Cuisset T., Morange P.E., et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101 (2008) 1088-1093
20. Giusti B., Gori A.M., Marcucci R., et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17 (2007) 1057-1064
21. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008) 1925-1934
22. Andersson T., Flockhart D.A., Goldstein D.B., et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 78 (2005) 559-581
23. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 (2005) 2211-2221
24. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 2567-2573
25. Cutlip D., Windecker S., Mehran R., et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
26. Furata T., Shirai N., Xiao F., Ohashi K., and Ishizaki T. Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70 (2001) 484-492
27. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol 51 (2008) 256-260
28. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster p2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
29. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 115 (2007) 708-716
30. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
32. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
33. Angiolillo D.J., Bernardo E., Palazuelos J., et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 99 (2008) 161-168
34. Angiolillo D.J., Bernardo E., Sabaté M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
35. Bliden K.P., Dichiara J., Tantry U.S., et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
36. Collet J.P., Silvain J., Landivier A., et al. Dose-effect of clopidogrel re-loading in patients already on 75 mg maintenance dose: the RELOAD study. Circulation 118 (2008) 1225-1233
37. Steinhubl S.R., Berger S., Mann J.T., et al., for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288 (2002) 2411
38. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., and Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
39. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
40. Hamsten A., Wiman B., De Faire U., and Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1557-1563
41. Bertrand-Thiébault C., Berrahmoune H., Thompson A., et al. Genetic polymorphism of CYP2C19 gene in the stanislas cohort. A link with inflammation. Ann Hum Genet 72 (2008) 178-183
42. Franco E., Palumbo L., Crobu F., et al. Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. BMC Med Genet 8 (2007) 27
43. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606